2005 - Jan 13th CTIC
yahoo post ........
the * and bold are mine
CTIC's next scheduled presentation will be at the Piper Jaffray Health Care Conference, to be held Jan 25-27.
In Nov we got a lot of details on Stellar 3 enrollment, cumulative events, patient demographics, etc. In Dec, we got similar information in Stellar-4.
*************************
Will January be Stellar-2 month? We are now nearly 7 months from the end of enrollement. Although some patients could still be getting cycles of treatment, every patient will have had the opportunity (if they were able) to get at least 10 cycles of treatment. 6-8 months is about the expected median survival in that patient population. There were 447 deaths (out of 850) as of Oct.
An update similar to what we got with 3&4 would really give us a sense of how well this trial is doing. Unlike 3&4, for St-2 we have extremely detailed information from a large and very recent P-III trial, the Alimta trial, using the same control treatment.
A "Wachovia" type presentation on Stellar 2 (consisting of actual enrollment, cumulative deaths, cycle data, and a breakdown of the patient characteristics) would give us a pretty good picture of what to expect in the control group (to the extent the St-2 patients match the Alimta patients) and a pretty good sense of how xyotax is working.
*************************
If you're interested: here's a link to the FDA's report prepared for the ODAC on the Alimta trial.
fda.gov
messages.yahoo.com
Additional timelines are as follows - also from Yahoo
>>>>>>>>>>>>>>>>
The next three presentations are the following:
Jan. 25-27 Piper Jaffray Health Care Conference
New York
Feb. 22 CTI 4Q04 Financials Conference Call
Feb. 23-24 BIO CEO & Investor Conference 2005
New York
What is expected is further information on progress in Stellars 3 and 4.
>>>>>>>>>>>>>>>>
finance.messages.yahoo.com
finance.messages.yahoo.com |
